Menu Search
Equities

Helix Biopharma Corp

HBPCF:PKC

Helix Biopharma Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1377
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-5.03%
  • Beta--
Data delayed at least 15 minutes, as of Mar 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Helix BioPharma Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2).

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-5.65m
  • Incorporated2008
  • Employees9.00
  • Location
    Helix Biopharma Corp401 Bay Street,, Suite 2704,PO Box 4TORONTO M5H 2Y4CanadaCAN
  • Phone+1 (905) 841-2300
  • Fax+1 (905) 841-2244
  • Websitehttps://www.helixbiopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.